Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.83 +3.2%	$4.12	$2.90 ▼ $11.16	$338.02M	-0.01	2.97 million shs	2.74 million shs
LLY Eli Lilly and Company	$732.41 +0.1%	$748.68	$623.78 ▼ $969.65	$693.36B	0.44	6.90 million shs	2.55 million shs
NVO Novo Nordisk A/S	$56.51 +0.7%	$60.72	$45.05 ▼ $139.74	$252.09B	0.63	20.46 million shs	9.10 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	+3.23%	+8.19%	+4.93%	-29.47%	-40.90%
LLY Eli Lilly and Company	+0.02%	+3.05%	-3.60%	-0.80%	-22.82%
NVO Novo Nordisk A/S	+0.70%	-0.68%	+12.92%	-20.86%	-57.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	3.256 of 5 stars	4.3	3.0	0.0	0.0	2.4	1.7	0.6
LLY Eli Lilly and Company	5 of 5 stars	4.3	5.0	3.3	4.0	3.1	3.3	3.8
NVO Novo Nordisk A/S	4.573 of 5 stars	4.1	5.0	2.5	0.0	2.6	0.0	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$17.40	354.31% Upside
LLY Eli Lilly and Company	2.67	Moderate Buy	$950.17	29.73% Upside
NVO Novo Nordisk A/S	2.13	Hold	$81.00	43.35% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Reduce ➝ Hold	$675.00 ➝ $700.00
8/27/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
8/22/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2025	NVO Novo Nordisk A/S	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/19/2025	NVO Novo Nordisk A/S	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$105.00 ➝ $70.00
8/17/2025	LLY Eli Lilly and Company	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$700.00
8/17/2025	LLY Eli Lilly and Company	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	NVO Novo Nordisk A/S	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral
8/13/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,901.79	N/A	N/A	$1.83 per share	2.09
LLY Eli Lilly and Company	$45.04B	15.39	$14.23 per share	51.46	$19.39 per share	37.77
NVO Novo Nordisk A/S	$42.12B	5.99	$3.90 per share	14.47	$5.73 per share	9.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	11/11/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	47.87	23.54	1.02	25.91%	92.72%	16.89%	10/29/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.64	15.52	12.13	1.96	35.60%	78.64%	24.51%	11/5/2025 (Estimated)

Latest LLY, NVO, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/6/2025	Q2 2025	NVO Novo Nordisk A/S	$0.93	$0.97	+$0.04	$0.91	$77.51 billion	$11.69 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.82%	N/A	39.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.45%	N/A	22.53%	N/A

Latest LLY, NVO, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025
8/6/2025	NVO Novo Nordisk A/S	semi-annual	$0.4119	2.4%	8/18/2025	8/18/2025	8/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
LLY Eli Lilly and Company	1.86	1.28	1.00
NVO Novo Nordisk A/S	0.52	0.78	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.40%
LLY Eli Lilly and Company	0.13%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.37 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
NVO Novo Nordisk A/S	77,349	4.47 billion	4.46 billion	Optionable

LLY, NVO, and ALT Headlines

Recent News About These Companies

Aperture Investors LLC Grows Stock Position in Novo Nordisk A/S $NVO

August 30 at 7:54 AM | marketbeat.com

Evergreen Capital Management LLC Boosts Stake in Novo Nordisk A/S $NVO

August 30 at 7:25 AM | marketbeat.com

Parnassus Investments LLC Grows Position in Novo Nordisk A/S $NVO

August 30 at 6:41 AM | marketbeat.com

Join Class Action to Recover Losses from Novo Nordisk A/S (NVO) - Contact Levi & Korsinsky Before September 30, 2025

August 30 at 2:24 AM | theglobeandmail.com

Denmark cuts growth forecast amid troubles for Novo Nordisk

August 29 at 4:24 PM | msn.com

DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

August 29 at 12:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO

August 29 at 10:00 AM | globenewswire.com

Trexquant Investment LP Increases Stock Position in Novo Nordisk A/S $NVO

August 29 at 8:04 AM | marketbeat.com

Gerber Kawasaki Wealth & Investment Management Sells 18,218 Shares of Novo Nordisk A/S $NVO

August 29 at 7:43 AM | marketbeat.com

Novo Nordisk woes prompt Denmark to slash country's 2025 growth forecast

August 29 at 6:36 AM | msn.com

Ozempic Maker Novo Nordisk Is a Problem as Denmark's Economy Hits a Wall

August 29 at 6:12 AM | barrons.com

Denmark slashes 2025 growth forecast amid Novo Nordisk slowdown

August 29 at 3:11 AM | cnbc.com

NVO LAWSUIT ALERT: Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline

August 29 at 2:36 AM | theglobeandmail.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

August 28 at 5:15 PM | globenewswire.com

Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

August 28 at 4:41 PM | globenewswire.com

Contact Levi & Korsinsky by September 30, 2025 to Join Class Action Against Novo Nordisk A/S (NVO)

August 28 at 3:34 PM | theglobeandmail.com

Growth Stocks To Add to Your Watchlist - August 27th

August 28 at 2:33 PM | marketbeat.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO

August 28 at 1:17 PM | globenewswire.com

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

August 28 at 11:17 AM | globenewswire.com

Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights

August 28 at 10:13 AM | globenewswire.com

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO

August 28 at 8:45 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, NVO, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.83 +0.12 (+3.23%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$3.79 -0.04 (-1.15%)

As of 08/29/2025 07:58 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Eli Lilly and Company NYSE:LLY

$732.41 +0.45 (+0.06%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$731.25 -1.16 (-0.16%)

As of 08/29/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$56.50 +0.40 (+0.70%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$56.45 -0.05 (-0.10%)

As of 08/29/2025 08:00 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time